Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 4/20 | 0.50 |
| ▸ | CTSL | P07711 | 4/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31235862 | 0.90 | CTSV (0.48) | CTSVCTSLCYP19A1PTGESMEN1 | |
| SCHEMBL582235 | 0.87 | CTSV (0.60) | CTSVCTSLCYP19A1PTGESNPC1 | |
| SCHEMBL31235825 | 0.87 | CTSV (0.60) | CTSVCTSLCYP19A1PTGESNPC1 | |
| SCHEMBL11922562 | 0.85 | CTSV (0.53) | CTSVCTSLCYP19A1MEN1MAPT | |
| SCHEMBL2682298 | 0.83 | CTSV (0.49) | CTSVCTSLCYP19A1BRD4PTGES | |
| SCHEMBL5064933 | 0.81 | BRD4 (0.47) | CTSVCTSLCYP19A1BRD4KMT2A | |
| SCHEMBL13504298 | 0.80 | CTSV (0.54) | CTSVCTSLCYP19A1PTGESMEN1 | |
| SCHEMBL1137268 | 0.80 | PTGES (0.57) | CTSVCTSLCYP19A1PTGESMEN1 | |
| SCHEMBL14050163 | 0.80 | THRA (0.43) | CYP19A1MEN1MAPTKMT2A | |
| SCHEMBL5064967 | 0.80 | BACE1 (0.51) | CTSVCTSLMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432392-B2 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432392-B2 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060205726-A1 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2006-09-14 | — | — | US | disclosed |
| EP-1669345-A1 | ESTER DERIVATIVE AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205726-A1 | Ester derivatives and medical use thereof | MTTP, LIPC, CETP | CTSV 3390/4885CTSL 1489/4885CYP19A1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.